https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Thu, 26 Aug 2021 17:46:33 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png https://mirror.vjregenmed.com 32 32 https://mirror.vjregenmed.com/video/4edottx-bg0-second-cd19-targeted-car-t-cell-infusion-for-rr-b-cell-malignancies/ Fri, 26 Feb 2021 14:08:26 +0000 http://13.40.107.223/video/4edottx-bg0-second-cd19-targeted-car-t-cell-infusion-for-rr-b-cell-malignancies/ CD19 CAR T-cells are transforming the treatment of relapsed or refractory (R/R) B-cell malignancies. However, complete responses are not seen in all patients, and in a significant proportion, these responses are not durable. Jordan Gauthier, MD, MSc, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses second infusions of CD19 CAR T-cells (CART2) as a possible approach to improve outcomes in patients with R/R B-cell malignancies. An analysis of the outcomes after CART2 in patients with R/R acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia treated on a Phase I/II clinical trial of CD19 CAR T-cells of defined composition showed that CART2 was feasible and safe in most patients. Additionally, two modifiable pre-treatment factors independently associated with better outcomes after CART2 were identified. This interview took place during the 3rd European CAR T-cell Meeting.

]]>